The new understanding of molecular events that drive the various forms of amyloidosis has generated treatment strategies that ...

ATTR amyloidosis results from the buildup of transthyretin in the body. It can be inherited or acquired and can affect your heart, kidneys, and nervous system. While there’s no cure, treatment ...

The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

Amyloidosis is a rare, multisystem disease that leads to deposition of misfolded proteins in various organs. This case report ...

Amyloidosis is a rare condition defined by the abnormal production of proteins that bind together to form amyloid proteins.

Eplontersen is recommended, within its marketing authorisation, as an option for treating hereditary transthyretin-related amyloidosis in adults with stage 1 or stage 2 polyneuropathy. It is only ...

which has significant implications in oncology since there are treatment similarities between AL amyloidosis and certain blood cancers such as multiple myeloma." Jessica Vermeulen, Vice President ...

The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...

The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research.

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

has granted orphan drug designation for AT-02 for the treatment of transthyretin-associated amyloidosis (ATTR), a rare, progressive, debilitating and often fatal condition. AT-02, the company’s ...